



## Advisory Board Report

The CgFARAD™ Advisory Board met virtually on November 11, 2022 and discussed the following items.

### Dr. Ronan Chapuis – New CgFARAD™ Team Member

CgFARAD™ recently added a new team member. Dr. Ronan Chapuis will provide French language translation services for withdrawal interval recommendations. There is the possibility he could join the pharmacology team in future.

Dr. Chapuis is originally from France and completed a large animal medicine residency and Masters degree at the Western College of Veterinary Medicine. After finishing his board exams and program, he and his wife (a small animal internist) accepted faculty jobs at Ross University School of Veterinary Medicine on St Kitts.

Ronan has been working as an equine clinician but will be transitioning into the Biomedical Sciences Department as a pharmacologist. He will also be completing an ACVCP alternative program under CgFARAD™ Co-director, Dr. Trisha Dowling. Dr. Dowling will also be on Ronan's PhD committee. His PhD project will involve drug residues in food animals.

### Antimicrobial Use Education and Outreach

CgFARAD™ is committed to promoting prudent antimicrobial use and antimicrobial resistance mitigation. When responding to withdrawal inquiries, CgFARAD™ has enhanced the information and guidance regarding prudent antimicrobial use, e.g., recommendations for alternative products, questioning use/dosage/duration, etc.

Co-Directors Dr. Ron Johnson and Dr. Trisha Dowling, and CgFARAD™ Administrator Susan Fitzgerald along with J.T. McClure (University of Prince Edward Island) and Mike Apsley (Kansas State University) have been working on putting together a two-part virtual seminar on research related to prudent drug use in the first quarter of 2023. The primary focus is food animals but research in other species with a potential application to food animals will be entertained. The concept is to provide an opportunity for graduate students to showcase what they are working on and introduce them to other students and lead researchers in the field. Audience invitees will be students, academics and CgFARAD™ stakeholders.

We are also proposing to produce some taped webinars which will be posted on the CgFARAD™ website. Topics will include explaining the regulatory framework, dispelling myths regarding residue avoidance, etc.

### Access to Veterinary Medicinal Products

CgFARAD™ Administrator, Susan Fitzgerald has been coordinating meetings with the Canadian Animal Health Institute, the national commodity groups and national veterinarian associations regarding access to veterinary medicinal products. A roundtable was held in February 2022 with the Veterinary Drugs Directorate (VDD), and another is scheduled for January 2023. Over the summer, there were bilateral meetings between the VDD and individual commodity sectors. Discussions are related to regulatory

barriers, challenges, and gaps that put Canadian agriculture at a competitive disadvantage as well as pose an animal welfare risk.

Co-Director Dr. Trisha Dowling has been involved with the VDD discussions with the national groups and will also be engaged in the new VDD pilot project looking at label claims on antimicrobials for usage in excess of 14 days.

## Financial Support of CgFARAD™ Activities

All stakeholder financial contributions have been received for 2022-2023 including a contribution of \$150,000 from the Canadian Food Inspection Agency. This is the second year we have received financial support from CFIA which will be used toward research relating to withdrawal recommendations, for antimicrobial use education and awareness, and French language service support as well as our on-going operations.

Last year, the CgFARAD™ Advisory Board approved an annual increase of 4% to stakeholder financial contributions to offset increasing operational costs. The funds received from the CFIA assist us to expand and sustain CgFARAD™ services.

## CgFARAD™ Research Projects

In this year's budget, the CgFARAD™ Advisory Board allocated up to \$50,000 to contribute to research projects related to withdrawal recommendations and food residue depletion work.

### **Dexamethasone**

The Dexamethasone Depletion in Lactating Dairy Cattle and Beef Cattle project has concluded. It was funded by OMAFRA-UGuelph (Alliance), the Dairy Farmers of Ontario and the Beef Farmers of Ontario. Results of these two studies will assist veterinarians with rational withdrawal times that can ensure human food safety. The research paper will be submitted for publication in the Journal of Veterinary Pharmacology and Therapeutics.

### **Fluralaner**

Mites and lice are a problem for both commercial and backyard flocks. Pesticides cannot be used in an extra-label manner so CgFARAD™ cannot give withdrawal recommendations. Fluralaner should soon be registered in Canada for control of mites in poultry. The product is anticipated to have a zero withdrawal time for eggs in Canada, as it does in the European Union. Unfortunately for the backyard flocks, the smallest size of the product is a container that treats 10,000 birds. CgFARAD™ Co-Directors Dowling and Johnson, Dr. Karen Schwean-Lardner (USask) and a CFIA scientist received funding from Egg Farmers of Canada to investigate the use of dog (tablets) and cat (topical) formulations of fluralaner to determine if they would be suitable for use on small flocks of layers.

### **Needle-free Administration versus Intramuscular Injection in Piglets**

CgFARAD™ Co-Director Dr. Ron Johnson and Dr. Terri O'Sullivan, University of Guelph have submitted a funding proposal for a project looking at the efficacy, animal welfare, and pharmacokinetic impacts of needle-free administration of iron dextran and meloxicam compared to intramuscular injection in piglets. If approved, \$20,000 of the \$50,000 budgeted for CgFARAD™ research will be applied to the project.